Loading clinical trials...

Neuropathic Pain Syndrome Patient Study (MK-0000-072) | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug

NCT00570310•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient has moderate to severe nerve pain due to one of the following conditions: Postherpetic neuralgia, Painful diabetic neuropathy, Small fiber neuropathy or idiopathic distal sensory polyneuropathy
•Patient is able to complete questionnaires in either English or Spanish
•Patient is at least 18 years of age

Exclusion Criteria

•Patient is either pregnant or breastfeeding
•Patient has a history of angioedema (swelling beneath the skin surface) or peripheral edema (foot, leg, and/or ankle swelling)
•Patient has a history of congestive heart failure
•Patient has a seizure disorder
•Patient has a history of drug and/or alcohol abuse within the past 1 year
•Patient failed treatment due to lack of pain relief with more than three drugs for nerve pain
•Patient has had cancer (except basal cell carcinoma) within the past two years
•Patient anticipates the need for surgery while participating in the study
•Patient has a reported history of hepatitis B, C, or HIV infection
•Patient has another type of pain that is more painful than the nerve pain
+2 more criteria

Key Dates

Start Date

December 1, 2007

Primary Completion Date

September 1, 2008

Completion Date

September 1, 2008

Last Updated

May 7, 2015

Enrollment

104

ACTUAL participants

Conditions

Neuralgia, PostherpeticDiabetic NeuropathyPainful Small-Fiber NeuropathyIdiopathic Distal Sensory Polyneuropathy

Interventions

Comparator: pregabalin

DRUG

Comparator: Placebo (unspecified)

DRUG

The Association Between Cognitive Function and Neuropathy in Individuals With Type 2 Diabetes

NCT06857994

Peripheral Diabetic NeuropathyCardiovascular Autonomic Neuropathy+2 more

View study

ENROLLING_BY_INVITATIONNA

Comparison of Active vs Passive Neural Mobilizations Effects in Improving Burning Pain, Muscular Strength, and Range of Motion in Patients With Diabetic Neuropathy

NCT07141992

NeuropathyDiabete Mellitus+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

Inclusion Criteria

Exclusion Criteria

The Association Between Cognitive Function and Neuropathy in Individuals With Type 2 Diabetes

Comparison of Active vs Passive Neural Mobilizations Effects in Improving Burning Pain, Muscular Strength, and Range of Motion in Patients With Diabetic Neuropathy

Evaluation and Treatment for Diabetic Peripheral Neuropathy

Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation

Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients

Effect of Gluten-Free Dietary Education and Intraneural Facilitation® Therapy on Quality of Life in People With Diabetic Neuropathy